HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes

SIMPLE SUMMARY: In the current clinical practice, HER2 status is tested in breast and gastroesophageal cancers to select patients eligible for anti-HER2 treatment. However, HER2 is an emerging biomarker in colorectal cancer (CRC), one of the big killers in oncology. The most frequent types of HER2 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanova, Mariia, Venetis, Konstantinos, Guerini-Rocco, Elena, Bottiglieri, Luca, Mastropasqua, Mauro Giuseppe, Garrone, Ornella, Fusco, Nicola, Ghidini, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502498/
https://www.ncbi.nlm.nih.gov/pubmed/36143438
http://dx.doi.org/10.3390/life12091403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502498/
https://www.ncbi.nlm.nih.gov/pubmed/36143438
http://dx.doi.org/10.3390/life12091403

Ejemplares similares